Search results
Results from the WOW.Com Content Network
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
Japan-based Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) announced a strategic investment to support the advancement of Taysha Gene Therapies Inc's (NASDAQ: TSHA) adeno-associated virus (AAV ...
The U.S. government, late last month, selected the first 10 drugs, including the top-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, which will face price negotiations as part ...
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The top 5 best selling pharmaceuticals 2015–2019. Sales in billion USD. [1] Rank Drug ... Astellas Pharma US: Overactive bladder: Feb-2000: 2018-Nov 68: Dexilant:
A woman who underwent a trial immunotherapy as a child for neuroblastoma — an aggressive nerve tissue tumor that occurs often in children under 5 — has since been in remission for 18 years ...
The treatment is being developed by Astellas Gene Therapies and is currently in a phase I/II clinical trial in the United States. As of October 2021, four children had died in the trial after experiencing liver failure linked to the treatment, and the trial has been placed on clinical hold by the U.S. Food and Drug Administration .